TY - JOUR
T1 - Selective oestrogen receptor modulators in prevention of breast cancer
T2 - An updated meta-analysis of individual participant data
AU - Cuzick, Jack
AU - Sestak, Ivana
AU - Bonanni, Bernardo
AU - Costantino, Joseph P.
AU - Cummings, Steve
AU - DeCensi, Andrea
AU - Dowsett, Mitch
AU - Forbes, John F.
AU - Ford, Leslie
AU - LaCroix, Andrea Z.
AU - Mershon, John
AU - Mitlak, Bruce H.
AU - Powles, Trevor
AU - Veronesi, Umberto
AU - Vogel, Victor
AU - Wickerham, D. Lawrence
PY - 2013
Y1 - 2013
N2 - Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the duration of the effect is unknown. We assessed the effectiveness of selective oestrogen receptor modulators (SERMs) on breast cancer incidence. Methods We did a meta-analysis with individual participant data from nine prevention trials comparing four selective oestrogen receptor modulators (SERMs; tamoxifen, raloxifene, arzoxifene, and lasofoxifene) with placebo, or in one study with tamoxifen. Our primary endpoint was incidence of all breast cancer (including ductal carcinoma in situ) during a 10 year follow-up period. Analysis was by intention to treat. Results We analysed data for 83 399 women with 306 617 women-years of follow-up. Median follow-up was 65 months (IQR 54-93). Overall, we noted a 38% reduction (hazard ratio [HR] 0·62, 95% CI 0·56-0·69) in breast cancer incidence, and 42 women would need to be treated to prevent one breast cancer event in the first 10 years of follow-up. The reduction was larger in the first 5 years of follow-up than in years 5-10 (42%, HR 0·58, 0·51-0·66; p
AB - Background Tamoxifen and raloxifene reduce the risk of breast cancer in women at elevated risk of disease, but the duration of the effect is unknown. We assessed the effectiveness of selective oestrogen receptor modulators (SERMs) on breast cancer incidence. Methods We did a meta-analysis with individual participant data from nine prevention trials comparing four selective oestrogen receptor modulators (SERMs; tamoxifen, raloxifene, arzoxifene, and lasofoxifene) with placebo, or in one study with tamoxifen. Our primary endpoint was incidence of all breast cancer (including ductal carcinoma in situ) during a 10 year follow-up period. Analysis was by intention to treat. Results We analysed data for 83 399 women with 306 617 women-years of follow-up. Median follow-up was 65 months (IQR 54-93). Overall, we noted a 38% reduction (hazard ratio [HR] 0·62, 95% CI 0·56-0·69) in breast cancer incidence, and 42 women would need to be treated to prevent one breast cancer event in the first 10 years of follow-up. The reduction was larger in the first 5 years of follow-up than in years 5-10 (42%, HR 0·58, 0·51-0·66; p
UR - http://www.scopus.com/inward/record.url?scp=84878107936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878107936&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(13)60140-3
DO - 10.1016/S0140-6736(13)60140-3
M3 - Article
C2 - 23639488
AN - SCOPUS:84878107936
VL - 381
SP - 1827
EP - 1834
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9880
ER -